On October 3, 2014, ProQR Therapeutics N.V. announced the appointment of Smital Shah as its new Chief Financial Officer, effective immediately. Ms. Shah has a track record of management and leadership experience in the biopharmaceutical industry as well as in investment banking, with a particular focus on financial strategy and capital markets. Ms. Shah joins the company from Gilead Sciences Inc.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.66 USD | +0.61% |
|
-2.92% | -16.16% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.16% | 14Cr | |
+15.20% | 12TCr | |
+19.67% | 11TCr | |
+18.95% | 2.6TCr | |
-23.86% | 1.94TCr | |
-19.03% | 1.59TCr | |
-20.90% | 1.51TCr | |
-46.14% | 1.51TCr | |
+63.85% | 1.49TCr | |
+4.49% | 1.39TCr |
- Stock Market
- Equities
- PRQR Stock
- News ProQR Therapeutics N.V.
- ProQR Therapeutics N.V. Appoints Smital Shah as Chief Financial Officer